Table 1.
Ongoing clinical trials investigating combined anti-angiogenic therapy and immune checkpoint inhibitors.
| Tumor type | Name (trial ID) | Phase | Setting | N | Treatment arm |
|---|---|---|---|---|---|
| RCC | CLEAR (NCT02811861) | III | 1st | 1069 | Pembrolizumab + lenvatinib vs. lenvatinib + everolimus vs. sunitinib |
| RCC | CheckMate9ER (NCT03141177) | III | 1st | 701 | Nivolumab + cabozantinib vs. sunitinib |
| RCC | CONTACT-03 (NCT04338269) | III | ≥2nd | 500 | Atezolizumab + cabozantinib vs. cabozantinib |
| HCC | LEAP-002 (NCT03713593) | III | 1st | 750 | Pembrolizumab + lenvatinib vs. lenvatinib |
| HCC | IMbrave050 (NCT04102098) | III | adjuvant | 662 | Atezolizumab + bevacizumab vs. active surveillance |
| HCC | COSMIC-312 (NCT03755791) | III | 1st | 740 | Atezolizumab + cabozantinib vs. sorafenib vs. cabozantinib |
| NSCLC | NCT02039674 | I/II | 1st | 267 | Pembrolizumab + chemotherapy + bevacizumab/ipilimumab/anti-EGFR |
| Colorectal | COMMIT (NCT02997228) | III | 1st | 347 | Atezolizumab + bevacizumab + mFOLFOX6 vs. bevaziaumb+mFOLFOX6 vs. atezolizumab |
| Gastric | SEQUEL (NCT04069273) | II | ≥2nd | 58 | Pembrolizumab + ramucirumab + paclitaxel |
| Melanoma | NCT01950390 | II | 1st, 2nd | 168 | Ipilimumab + bevacizumab |
| Urothelial | NCT03272217 | II | 1st | 70 | Atezolizumab + bevacizumab |
| Solid tumors | NCT02443324 | II | ≥2nd | 155 | Pembrolizumab + ramucirumab |
RCC renal cell carcinoma, HCC hepatocellular carcinoma, NSCLC non-small cell lung cancer.